FILE PHOTO: A sign marks the headquarters of Moderna Therapeutics, which is developing a vaccine against coronavirus (COVID-19), in Cambridge, Massachusetts, USA, May 18, 2020. REUTERS / Brian Snyder (Reuters) – Drug Developer Moderna Inc (MRNA.O) on Friday said it has so far enrolled 13,194 participants in the ongoing 30,000-volunteer …
Read More »
(Reuters) – The following is a roundup of some of the latest scientific studies on the new coronavirus and efforts to find treatments and vaccines for COVID-19, the disease caused by the virus. New questions about inhibitor COVID-19 efficacy A new study raises fresh questions about the effectiveness of Gilead …
Read More »
(Reuters) – The U.S. Food and Drug Administration was able to update its emergency use authorization for Gilead Sciences Inc’s (GILD.O) brakesivir of drugs to admit patients admitted to hospital with moderate COVID-19, despite mixed test results, the company’s top study said on Friday. FILE PHOTO: An ampoule of Ebola …
Read More »
CHICAGO / NEW YORK (Reuters) – Approximately one-fifth of the 11,000 people enrolled in a 30,000-volunteer U.S. trial of a Pfizer COVID-19 vaccine (PFE.N) and German partner BioNTech (22UAy.F) are Black as Latino, groups among the hardest hit by the coronavirus virus pandemic, said a top Pfizer executive. PHILO PHOTO: …
Read More »
LONDON (Reuters) – Russia’s plan to roll out its “Sputnik-V” COVID-19 vaccine, even before full studies show how well it works, requires concern among virus experts, who warn of a partially effective shot at the new encourage coronavirus to mutate. PHILO PHOTO: A handout photo provided by the Russian Direct …
Read More »